Sangamo Therapeutics, Inc. reported impairment results for the fourth quarter ended December 31, 2023. For the quarter, the company reported Impairment of long-lived assets of $0.3 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.529 USD | -4.82% | +1.21% | -2.71% |
Mar. 22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
Mar. 14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.71% | 115M | |
+8.70% | 105B | |
-0.87% | 104B | |
+5.79% | 22.94B | |
-12.49% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.07% | 16.96B | |
+8.23% | 14.16B | |
+39.22% | 12.63B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023